Reviva Pharmaceuticals (NASDAQ:RVPH) Rating Reiterated by HC Wainwright

HC Wainwright restated their buy rating on shares of Reviva Pharmaceuticals (NASDAQ:RVPH) in a research report sent to investors on Thursday morning, Benzinga reports. They currently have a $14.00 target price on the stock.

Separately, Benchmark reiterated a speculative buy rating and issued a $17.00 price target on shares of Reviva Pharmaceuticals in a report on Tuesday, May 28th.

Reviva Pharmaceuticals Stock Performance

NASDAQ:RVPH opened at $1.25 on Thursday. The firm has a market capitalization of $34.90 million, a PE ratio of -0.79 and a beta of -0.09. The stock’s fifty day moving average is $2.07 and its 200 day moving average is $3.31. Reviva Pharmaceuticals has a fifty-two week low of $1.21 and a fifty-two week high of $6.80.

Reviva Pharmaceuticals (NASDAQ:RVPH) last released its earnings results on Tuesday, May 14th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.03. Equities analysts forecast that Reviva Pharmaceuticals will post -0.98 EPS for the current year.

Institutional Trading of Reviva Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of RVPH. Vontobel Holding Ltd. purchased a new stake in Reviva Pharmaceuticals in the fourth quarter worth about $72,000. Vanguard Group Inc. raised its holdings in shares of Reviva Pharmaceuticals by 2.8% in the 1st quarter. Vanguard Group Inc. now owns 1,001,836 shares of the company’s stock valued at $3,787,000 after purchasing an additional 26,854 shares in the last quarter. Finally, Armistice Capital LLC lifted its position in shares of Reviva Pharmaceuticals by 194.0% in the 4th quarter. Armistice Capital LLC now owns 1,764,000 shares of the company’s stock worth $9,085,000 after purchasing an additional 1,164,000 shares during the period. Institutional investors own 63.18% of the company’s stock.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.